



Drug and Gene Delivery Nanoformulations against Cancer Hallmarks

Guest Editors:

Dr. Eduardo Ruiz-Hernandez

Dr. Amelia Ultimo

Dr. Luiza C. S. Erthal

Deadline for manuscript
submissions:

closed (20 May 2022)

Message from the Guest Editors

Dear Colleagues,

In 2000, Hanahan and Weinberg proposed a list of six advantageous and complementary biological capabilities that enable tumour growth, survival, and metastatic dissemination, the so-called hallmarks of cancer, with the aim to reduce the intricacy of cancer biology. Such list included sustained proliferative signalling, insensitivity to growth suppressors, cell death resistance, replicative immortality, sustained angiogenesis, and tissue invasion and metastasis. Years later, they added typical cancer features to the list, such as altered energy metabolism and immune surveillance evasion. The definition of cancer hallmarks has encouraged the development of specific therapeutic approaches directed to their inhibition, which is expected to slow down/prevent cancer growth.

This Special Issue aims to bring together recently developed therapeutic strategies based on drug/gene nanocarriers targeted to obstacle tumour progression acting on one or multiple hallmarks. We invite reviews or articles on all aspects of “Drug and Gene Delivery Nanoformulations against Cancer Hallmarks”.

Dr. Eduardo Ruiz-Hernandez

Dr. Amelia Ultimo

Dr. Luiza C. S. Erthal

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma